The authors tested the effect of combined perioperative treatment using the β-blocker propranolol and the COX2-inhibitor etodolac that were administered for 20 perioperative days, starting 5 days before surgery, in patients with colorectal cancer on biomarkers of tumor metastasis, immunity, and inflammation. This evidence concerns the gene PTGS2 and neoplasm.